It has been reported that SOD expression levels and activity are downregulated or absent in a series of cancers, including ESCC (19-22), breast cancer (23), prostate cancer (24), and lung adenocarcinoma (25), compared to normal tissues. This evidence concerns the gene SOD1 and prostate cancer.